HCW Biologics Inc. (HCWB)
NASDAQ: HCWB · Real-Time Price · USD
0.430
0.00 (0.00%)
Nov 4, 2024, 4:00 PM EST - Market closed
HCW Biologics Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for HCW Biologics.
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for HCW Biologics.
Recommendation Trends
Rating | Jan '23 | Feb '23 | Mar '23 | Apr '23 | May '23 | Jun '23 |
---|---|---|---|---|---|---|
Strong Buy | 3 | 3 | 2 | 2 | 2 | 0 |
Buy | 0 | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 3 | 3 | 2 | 2 | 2 | 0 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
EF Hutton | EF Hutton | Strong Buy Initiates $9 | Strong Buy | Initiates | $9 | +1,993.02% | Jun 1, 2023 |
EF Hutton | EF Hutton | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +1,993.02% | Apr 19, 2023 |
EF Hutton | EF Hutton | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +1,993.02% | Mar 30, 2023 |
EF Hutton | EF Hutton | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +1,993.02% | Mar 23, 2023 |
JonesTrading | JonesTrading | Strong Buy Initiates $8 | Strong Buy | Initiates | $8 | +1,760.47% | Nov 8, 2022 |
Financial Forecast
Revenue This Year
1.15M
from 2.84M
Decreased by -59.53%
Revenue Next Year
n/a
from 1.15M
EPS This Year
-0.58
from -0.70
EPS Next Year
-0.56
from -0.58
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 1.2M | n/a | n/a | ||
Avg | 1.2M | n/a | n/a | ||
Low | 1.1M | n/a | n/a |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -58.4% | - | - | ||
Avg | -59.5% | - | - | ||
Low | -61.2% | - | - |
EPS Forecast
EPS | 2024 | 2025 | 2026 |
---|---|---|---|
High | -0.60 | -0.58 | -0.66 |
Avg | -0.58 | -0.56 | -0.64 |
Low | -0.56 | -0.54 | -0.62 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 |
---|---|---|---|
High | - | - | - |
Avg | - | - | - |
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.